MedTrace Logo

Special Drug Use Investigation - Assessment of Efficacy and Safety in Treating Secondary Infection of Chronic Respiratory Disease

NCT01690533 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 497

Last updated 2018-05-21

No results posted yet for this study

Summary

The objective of this study is to assess the efficacy and safety of Avelox Tablet 400 mg (hereinafter as "Avelox") in treating secondary infection of chronic respiratory disease.It is a local prospective and observational study of patients who have received Avelox tablets for Laryngopharyngitis, Tonsillitis, Bronchitis acute, Pneumonia, Secondary infection in chronic respiratory diseases, Sinusitis. A total of 500 patients are to be enrolled and assessed during the period of treatment with Avelox.

Conditions

  • Anti-Infective Agents

Interventions

DRUG

Avelox (Moxifloxacin, BAY12-8039)

Patients treated with Moxifloxacin in daily clinical practice

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-13
Primary Completion
2010-12-14
Completion
2013-07-19

Countries

  • Japan

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01690533 on ClinicalTrials.gov